Cargando…
Clinical Impact of 5 Years of Liraglutide Treatment on Cardiovascular Risk Factors in Patients with Type 2 Diabetes Mellitus in a Real-Life Setting in Italy: An Observational Study
INTRODUCTION: Based on existing data regarding the durability of liraglutide in type 2 diabetes, this study aimed to assess its long-term effectiveness at 5 years and its overall impact on cardiovascular (CV) risk. METHODS: This was a multicenter retrospective observational study. Liraglutide was us...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6250628/ https://www.ncbi.nlm.nih.gov/pubmed/30238228 http://dx.doi.org/10.1007/s13300-018-0503-4 |
_version_ | 1783372946934333440 |
---|---|
author | Frison, Vera Simioni, Natalino Marangoni, Alberto Balzano, Sara Vinci, Carmela Zenari, Luciano De Moliner, Lorena Tadiotto, Federica D’Ambrosio, Michele Confortin, Loris Marin, Narciso Lombardi, Simonetta Costa, Silvana Prosperini, Giuseppe Lapolla, Annunziata |
author_facet | Frison, Vera Simioni, Natalino Marangoni, Alberto Balzano, Sara Vinci, Carmela Zenari, Luciano De Moliner, Lorena Tadiotto, Federica D’Ambrosio, Michele Confortin, Loris Marin, Narciso Lombardi, Simonetta Costa, Silvana Prosperini, Giuseppe Lapolla, Annunziata |
author_sort | Frison, Vera |
collection | PubMed |
description | INTRODUCTION: Based on existing data regarding the durability of liraglutide in type 2 diabetes, this study aimed to assess its long-term effectiveness at 5 years and its overall impact on cardiovascular (CV) risk. METHODS: This was a multicenter retrospective observational study. Liraglutide was used under routine clinical practice conditions. Changes from baseline to 60 months in HbA1c, fasting plasma glucose (FPG), body weight, blood pressure, and lipid profile were assessed. United Kingdom Prospective Diabetes Study (UKPDS) scores were calculated at baseline and after 60 months to assess changes in the estimated 5- and 10-year risk for fatal and nonfatal coronary heart disease (CHD) and fatal and nonfatal stroke. RESULTS: Overall, 103 patients (age 59.0 ± 7.9 years, diabetes duration 10.4 ± 6.8 years) were involved in the study. After 60 months, HbA1c levels were reduced by − 1.0 ± 1.2%, FPG levels by − 24.5 ± 43.4 mg/dl, body weight by − 5.3 ± 6.4 kg, systolic blood pressure by − 6.5 ± 18.5 mmHg, diastolic blood pressure by − 3.6 ± 11.8 mmHg, and total cholesterol by − 16.9 ± 37.4 mg/dl. The proportion of patients achieving HbA1c levels of < 7% increased from 12.7% to 39.8% (p = 0.02). Based on the UKPDS scores, statistically significant reductions in the 5- and 10-year risk of nonfatal CHD and fatal CHD were found, with no change in the 5- and 10-year risk of fatal and nonfatal stroke. CONCLUSION: In patients prolonging treatment with liraglutide for 5 years, the benefits in relation to metabolic control and CV risk factors are maintained. The UKPDS risk scores suggest that liraglutide is associated with a reduced CHD risk, but not with a reduced stroke risk. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s13300-018-0503-4) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6250628 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-62506282018-12-07 Clinical Impact of 5 Years of Liraglutide Treatment on Cardiovascular Risk Factors in Patients with Type 2 Diabetes Mellitus in a Real-Life Setting in Italy: An Observational Study Frison, Vera Simioni, Natalino Marangoni, Alberto Balzano, Sara Vinci, Carmela Zenari, Luciano De Moliner, Lorena Tadiotto, Federica D’Ambrosio, Michele Confortin, Loris Marin, Narciso Lombardi, Simonetta Costa, Silvana Prosperini, Giuseppe Lapolla, Annunziata Diabetes Ther Original Research INTRODUCTION: Based on existing data regarding the durability of liraglutide in type 2 diabetes, this study aimed to assess its long-term effectiveness at 5 years and its overall impact on cardiovascular (CV) risk. METHODS: This was a multicenter retrospective observational study. Liraglutide was used under routine clinical practice conditions. Changes from baseline to 60 months in HbA1c, fasting plasma glucose (FPG), body weight, blood pressure, and lipid profile were assessed. United Kingdom Prospective Diabetes Study (UKPDS) scores were calculated at baseline and after 60 months to assess changes in the estimated 5- and 10-year risk for fatal and nonfatal coronary heart disease (CHD) and fatal and nonfatal stroke. RESULTS: Overall, 103 patients (age 59.0 ± 7.9 years, diabetes duration 10.4 ± 6.8 years) were involved in the study. After 60 months, HbA1c levels were reduced by − 1.0 ± 1.2%, FPG levels by − 24.5 ± 43.4 mg/dl, body weight by − 5.3 ± 6.4 kg, systolic blood pressure by − 6.5 ± 18.5 mmHg, diastolic blood pressure by − 3.6 ± 11.8 mmHg, and total cholesterol by − 16.9 ± 37.4 mg/dl. The proportion of patients achieving HbA1c levels of < 7% increased from 12.7% to 39.8% (p = 0.02). Based on the UKPDS scores, statistically significant reductions in the 5- and 10-year risk of nonfatal CHD and fatal CHD were found, with no change in the 5- and 10-year risk of fatal and nonfatal stroke. CONCLUSION: In patients prolonging treatment with liraglutide for 5 years, the benefits in relation to metabolic control and CV risk factors are maintained. The UKPDS risk scores suggest that liraglutide is associated with a reduced CHD risk, but not with a reduced stroke risk. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s13300-018-0503-4) contains supplementary material, which is available to authorized users. Springer Healthcare 2018-09-20 2018-12 /pmc/articles/PMC6250628/ /pubmed/30238228 http://dx.doi.org/10.1007/s13300-018-0503-4 Text en © The Author(s) 2018 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Research Frison, Vera Simioni, Natalino Marangoni, Alberto Balzano, Sara Vinci, Carmela Zenari, Luciano De Moliner, Lorena Tadiotto, Federica D’Ambrosio, Michele Confortin, Loris Marin, Narciso Lombardi, Simonetta Costa, Silvana Prosperini, Giuseppe Lapolla, Annunziata Clinical Impact of 5 Years of Liraglutide Treatment on Cardiovascular Risk Factors in Patients with Type 2 Diabetes Mellitus in a Real-Life Setting in Italy: An Observational Study |
title | Clinical Impact of 5 Years of Liraglutide Treatment on Cardiovascular Risk Factors in Patients with Type 2 Diabetes Mellitus in a Real-Life Setting in Italy: An Observational Study |
title_full | Clinical Impact of 5 Years of Liraglutide Treatment on Cardiovascular Risk Factors in Patients with Type 2 Diabetes Mellitus in a Real-Life Setting in Italy: An Observational Study |
title_fullStr | Clinical Impact of 5 Years of Liraglutide Treatment on Cardiovascular Risk Factors in Patients with Type 2 Diabetes Mellitus in a Real-Life Setting in Italy: An Observational Study |
title_full_unstemmed | Clinical Impact of 5 Years of Liraglutide Treatment on Cardiovascular Risk Factors in Patients with Type 2 Diabetes Mellitus in a Real-Life Setting in Italy: An Observational Study |
title_short | Clinical Impact of 5 Years of Liraglutide Treatment on Cardiovascular Risk Factors in Patients with Type 2 Diabetes Mellitus in a Real-Life Setting in Italy: An Observational Study |
title_sort | clinical impact of 5 years of liraglutide treatment on cardiovascular risk factors in patients with type 2 diabetes mellitus in a real-life setting in italy: an observational study |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6250628/ https://www.ncbi.nlm.nih.gov/pubmed/30238228 http://dx.doi.org/10.1007/s13300-018-0503-4 |
work_keys_str_mv | AT frisonvera clinicalimpactof5yearsofliraglutidetreatmentoncardiovascularriskfactorsinpatientswithtype2diabetesmellitusinareallifesettinginitalyanobservationalstudy AT simioninatalino clinicalimpactof5yearsofliraglutidetreatmentoncardiovascularriskfactorsinpatientswithtype2diabetesmellitusinareallifesettinginitalyanobservationalstudy AT marangonialberto clinicalimpactof5yearsofliraglutidetreatmentoncardiovascularriskfactorsinpatientswithtype2diabetesmellitusinareallifesettinginitalyanobservationalstudy AT balzanosara clinicalimpactof5yearsofliraglutidetreatmentoncardiovascularriskfactorsinpatientswithtype2diabetesmellitusinareallifesettinginitalyanobservationalstudy AT vincicarmela clinicalimpactof5yearsofliraglutidetreatmentoncardiovascularriskfactorsinpatientswithtype2diabetesmellitusinareallifesettinginitalyanobservationalstudy AT zenariluciano clinicalimpactof5yearsofliraglutidetreatmentoncardiovascularriskfactorsinpatientswithtype2diabetesmellitusinareallifesettinginitalyanobservationalstudy AT demolinerlorena clinicalimpactof5yearsofliraglutidetreatmentoncardiovascularriskfactorsinpatientswithtype2diabetesmellitusinareallifesettinginitalyanobservationalstudy AT tadiottofederica clinicalimpactof5yearsofliraglutidetreatmentoncardiovascularriskfactorsinpatientswithtype2diabetesmellitusinareallifesettinginitalyanobservationalstudy AT dambrosiomichele clinicalimpactof5yearsofliraglutidetreatmentoncardiovascularriskfactorsinpatientswithtype2diabetesmellitusinareallifesettinginitalyanobservationalstudy AT confortinloris clinicalimpactof5yearsofliraglutidetreatmentoncardiovascularriskfactorsinpatientswithtype2diabetesmellitusinareallifesettinginitalyanobservationalstudy AT marinnarciso clinicalimpactof5yearsofliraglutidetreatmentoncardiovascularriskfactorsinpatientswithtype2diabetesmellitusinareallifesettinginitalyanobservationalstudy AT lombardisimonetta clinicalimpactof5yearsofliraglutidetreatmentoncardiovascularriskfactorsinpatientswithtype2diabetesmellitusinareallifesettinginitalyanobservationalstudy AT costasilvana clinicalimpactof5yearsofliraglutidetreatmentoncardiovascularriskfactorsinpatientswithtype2diabetesmellitusinareallifesettinginitalyanobservationalstudy AT prosperinigiuseppe clinicalimpactof5yearsofliraglutidetreatmentoncardiovascularriskfactorsinpatientswithtype2diabetesmellitusinareallifesettinginitalyanobservationalstudy AT lapollaannunziata clinicalimpactof5yearsofliraglutidetreatmentoncardiovascularriskfactorsinpatientswithtype2diabetesmellitusinareallifesettinginitalyanobservationalstudy |